Kushenin Combined with Nucleos(t)‎ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis

Abstract EN

Objective.

To evaluate the efficacy and safety of Kushenin (KS) combined with nucleoside analogues (NAs) for chronic hepatitis B (CHB).

Methods.

Randomized controlled trials (RCTs) of KS combined with NAs for CHB were identified through 7 databases.

Frequencies of loss of serum HBeAg, HBeAg seroconversion, undetectable serum HBV-DNA, ALT normalization, and adverse events at 48 weeks were abstracted by two reviewers.

The Cochrane software was performed to assess the risk of bias in the included trials.

Data were analyzed with Review Manager 5.3 software.

Results.

18 RCTs involving 1684 subjects with CHB were included in the analysis.

KS combined with NAs including lamivudine (LAM), entecavir (ETV), adefovir dipivoxil (ADV), and telbivudine (TLV) showed different degree of improvement in CHB indices.

KS combined with NAs increased the frequency of loss of serum HBeAg, HBeAg seroconversion, undetectable HBV-DNA levels, and ALT normalization compared with single agents.

It also decreased serum ALT and AST level after one-year treatment.

However, KS combined with TLV did not show a significant difference in CHB indices.

The side-effects of KS combined with NAs were light and of low frequency.

Conclusion.

KS combined with NAs improves the efficacy of NAs in CHB.